Spago Nanomedical AB (publ) (SPAGO.ST)
SEK 0.22
(-0.92%)
SEK 0.22
(-0.92%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 19.79 Million SEK | 4.28% |
| 2022 | 23.48 Million SEK | 5.34% |
| 2021 | 22.29 Million SEK | 20.25% |
| 2020 | 18.53 Million SEK | -18.68% |
| 2019 | 22.79 Million SEK | 16.17% |
| 2018 | 19.62 Million SEK | 13.12% |
| 2017 | 17.34 Million SEK | 20.56% |
| 2016 | 14.38 Million SEK | -46.88% |
| 2015 | 27.08 Million SEK | 150.06% |
| 2014 | 10.83 Million SEK | 23.12% |
| 2013 | 8.79 Million SEK | 6.32% |
| 2012 | 8.27 Million SEK | 54.02% |
| 2011 | 5.37 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.18 Million SEK | -48.96% |
| 2024 Q2 | 3.54 Million SEK | 11.48% |
| 2023 Q2 | 5.42 Million SEK | 5.12% |
| 2023 Q3 | 5.08 Million SEK | -6.21% |
| 2023 FY | 24.48 Million SEK | 4.28% |
| 2023 Q4 | 6.23 Million SEK | 22.49% |
| 2023 Q1 | 5.15 Million SEK | -6.62% |
| 2022 FY | 23.48 Million SEK | 5.34% |
| 2022 Q1 | 6.08 Million SEK | 11.13% |
| 2022 Q4 | 5.52 Million SEK | 0.18% |
| 2022 Q3 | 5.51 Million SEK | -13.3% |
| 2022 Q2 | 6.36 Million SEK | 4.62% |
| 2021 Q3 | 4.75 Million SEK | -25.36% |
| 2021 Q1 | 5.69 Million SEK | 13.59% |
| 2021 Q4 | 5.47 Million SEK | 15.01% |
| 2021 Q2 | 6.37 Million SEK | 11.98% |
| 2021 FY | 22.29 Million SEK | 20.25% |
| 2020 FY | 18.53 Million SEK | -18.68% |
| 2020 Q1 | 4.99 Million SEK | -24.18% |
| 2020 Q2 | 4.33 Million SEK | -13.26% |
| 2020 Q3 | 4.2 Million SEK | -2.96% |
| 2020 Q4 | 5.01 Million SEK | 19.23% |
| 2019 Q2 | 5.37 Million SEK | -4.81% |
| 2019 Q4 | 6.58 Million SEK | 27.03% |
| 2019 Q3 | 5.18 Million SEK | -3.63% |
| 2019 FY | 22.79 Million SEK | 16.17% |
| 2019 Q1 | 5.65 Million SEK | 3.25% |
| 2018 Q1 | 4.85 Million SEK | -1.88% |
| 2018 Q3 | 4.56 Million SEK | -3.49% |
| 2018 Q4 | 5.47 Million SEK | 19.84% |
| 2018 FY | 19.62 Million SEK | 13.12% |
| 2018 Q2 | 4.73 Million SEK | -2.49% |
| 2017 Q3 | 4.1 Million SEK | -10.26% |
| 2017 Q4 | 4.94 Million SEK | 20.49% |
| 2017 FY | 17.34 Million SEK | 20.56% |
| 2017 Q1 | 3.72 Million SEK | 1.78% |
| 2017 Q2 | 4.57 Million SEK | 22.9% |
| 2016 Q1 | 3.75 Million SEK | -78.98% |
| 2016 FY | 14.38 Million SEK | -46.88% |
| 2016 Q4 | 3.65 Million SEK | 15.7% |
| 2016 Q3 | 3.16 Million SEK | -17.23% |
| 2016 Q2 | 3.81 Million SEK | 1.7% |
| 2015 Q3 | 2.7 Million SEK | -17.66% |
| 2015 Q2 | 3.27 Million SEK | 0.95% |
| 2015 Q1 | 3.24 Million SEK | 8.99% |
| 2015 Q4 | 17.85 Million SEK | 561.41% |
| 2015 FY | 27.08 Million SEK | 150.06% |
| 2014 FY | 10.83 Million SEK | 23.12% |
| 2014 Q4 | 2.98 Million SEK | 39.58% |
| 2014 Q3 | 2.13 Million SEK | -34.65% |
| 2014 Q2 | 3.26 Million SEK | 33.4% |
| 2014 Q1 | 2.44 Million SEK | 3.82% |
| 2013 Q1 | 2.56 Million SEK | 3.94% |
| 2013 Q3 | 2.44 Million SEK | 71.12% |
| 2013 Q4 | 2.35 Million SEK | -3.6% |
| 2013 FY | 8.79 Million SEK | 6.32% |
| 2013 Q2 | 1.43 Million SEK | -44.14% |
| 2012 FY | 8.27 Million SEK | 54.02% |
| 2012 Q4 | 2.46 Million SEK | 23.64% |
| 2012 Q2 | 1.93 Million SEK | 3.03% |
| 2012 Q3 | 1.99 Million SEK | 2.79% |
| 2012 Q1 | 1.88 Million SEK | 0.0% |
| 2011 FY | 5.37 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Asarina Pharma AB (publ) | 14.65 Million SEK | -35.058% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 93.845% |
| NextCell Pharma AB | -576.01 Thousand SEK | 3535.651% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 30.136% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 94.466% |
| AcouSort AB (publ) | 25.87 Million SEK | 23.52% |
| OncoZenge AB (publ) | 15.9 Million SEK | -24.426% |
| Xintela AB (publ) | 57.31 Million SEK | 65.472% |
| Ziccum AB (publ) | 27.87 Million SEK | 29.012% |
| Active Biotech AB (publ) | 44.8 Million SEK | 55.835% |
| Alzinova AB (publ) | 36.39 Million SEK | 45.626% |
| Amniotics AB (publ) | 29.07 Million SEK | 31.928% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 93.556% |
| BioArctic AB (publ) | 89.62 Million SEK | 77.92% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.693% |
| Camurus AB (publ) | 1.05 Billion SEK | 98.132% |
| Cantargia AB (publ) | 290.01 Million SEK | 93.176% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | 9.614% |
| CombiGene AB (publ) | 44.14 Million SEK | 55.17% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 86.16% |
| Genovis AB (publ.) | 88.19 Million SEK | 77.562% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 82.802% |
| Mendus AB (publ) | 129.13 Million SEK | 84.675% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -172.289% |
| Kancera AB (publ) | 63.07 Million SEK | 68.626% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -258.579% |
| LIDDS AB (publ) | 27.75 Million SEK | 28.69% |
| Lipum AB (publ) | 37.3 Million SEK | 46.954% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -172.815% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 85.439% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -20.663% |
| Saniona AB (publ) | 1.07 Million SEK | -1737.512% |
| Simris Alg AB (publ) | 38.64 Million SEK | 48.786% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 89.11% |
| Intervacc AB (publ) | 79.78 Million SEK | 75.196% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 53.579% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -11.915% |
| Corline Biomedical AB | 30.16 Million SEK | 34.401% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 65.898% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 76.205% |
| Aptahem AB (publ) | 10.01 Million SEK | -97.644% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 85.307% |
| Fluicell AB (publ) | 28.61 Million SEK | 30.845% |
| Biovica International AB (publ) | 133.72 Million SEK | 85.201% |
| Abliva AB (publ) | 27.86 Million SEK | 28.982% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 89.773% |
| 2cureX AB (publ) | 36.51 Million SEK | 45.808% |
| I-Tech AB | 40.14 Million SEK | 50.707% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 97.697% |
| Cyxone AB (publ) | 28.21 Million SEK | 29.858% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 81.905% |
| Biosergen AB | 26.8 Million SEK | 26.182% |
| Nanologica AB (publ) | 69.88 Million SEK | 71.683% |
| SynAct Pharma AB | 224.49 Million SEK | 91.185% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 55.202% |
| BioInvent International AB (publ) | 441.4 Million SEK | 95.517% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 17.384% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 93.17% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -151.901% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 82.157% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -34.626% |